SPY312.18+4.10 1.33%
DIA263.17+5.32 2.06%
IXIC9,682.91+74.54 0.78%

Morgan Stanley Maintains Overweight on Quest Diagnostics, Raises Price Target to $146

Morgan Stanley maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $139 to $146.

Benzinga · 05/20/2020 12:10

Morgan Stanley maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $139 to $146.